The court entered judgment approving the settlement on March 31, 2026. The April 17, 2025 claim deadline passed. The official administrator says it is processing claims and will notify class members about deficiencies, and that no payments will be issued until the settlement is final and all claims-processing activity is complete. No public distribution date has been announced.
StatusFinal Approval Granted; Claims Processing
Claim DeadlineApril 17, 2025 — Passed
Settlement Fund$100 Million
Historical ProofVaried by Claimant Type and Amount
The litigation alleged that Walgreens failed to include lower prices available through its Prescription Savings Club when reporting the usual and customary prices used to calculate insured prescription reimbursements. Plaintiffs contended that the practice caused insured consumers and third-party payors to pay inflated amounts.
Walgreens denied wrongdoing and maintained that it correctly reported its usual and customary prices. The $100 million settlement resolved the disputed claims without trial and also addressed the challenged Savings Club program under the agreement.
The class generally covers individuals and entities in the United States and its territories that paid, in whole or in part, for one or more Walgreens prescription drugs using prescription insurance benefits between January 1, 2007, and November 18, 2024. It includes individual consumers and qualifying third-party payors such as health plans and insurers.
Excluded groups include Walgreens and certain affiliates, pharmacy benefit managers, specified government entities, people who paid for every prescription without insurance benefits, and categories tied to other litigation or settlements as described in the notice.
Court-approved fees, expenses, administration, service awards, and other authorized costs are deducted from the gross fund. The plan of allocation divides the net fund between individual claimants and third-party payors, with 20% allocated to individuals and 80% allocated to the third-party payor pool.
Within each pool, payments are pro rata based on recognized claim amounts. No claimant was promised a fixed percentage of personal prescription spending or a particular check simply because the gross settlement totals $100 million.
Known individual claimants received identifying credentials and estimated their eligible Walgreens spending in ranges. A known individual claiming less than $10,000 generally could rely on the administrator’s identification without submitting purchase documentation, while a known claimant asserting $10,000 or more had to support that amount.
Unknown individual claimants had to provide records proving class membership and eligible prescription payments. The claim form and plan, rather than the existence of an insurance card alone, controlled whether the administrator recognized the submission.
Third-party payors had to submit data and documentation sufficient to identify eligible prescription reimbursements for covered members or beneficiaries. Their claims can involve large datasets, exclusions, coordination with vendors, and validation of amounts attributed to Walgreens prescriptions.
Because proof rules varied by claimant type and amount, the settlement is accurately labeled proof varies. It should not be summarized as universally no-proof or as requiring the same receipt from every consumer.
The court entered judgment and a final approval order on March 31, 2026. That written judgment—not the earlier scheduled fairness hearing—establishes that the settlement was approved. The administrator then moved into deficiency review and final claims processing.
Walgreens’s agreement to settle was not an admission that the plaintiffs’ theory was correct. Final approval means the court accepted the compromise as fair, reasonable, and adequate under the applicable rules.
The official website says no payments will be issued until the settlement is final and all claims-processing activities are complete. It does not provide a general distribution date. Earlier estimates that money might arrive in mid-to-late 2026 were projections, not administrator authorization.
The safe current description is payments pending during claims processing. The passage of time after judgment does not establish that finality, deficiency work, calculations, and payment authorization have all occurred.
A deficiency notice tells a claimant that the administrator needs additional information or identified a problem with the submission. The official update says such notices will be sent as processing continues. A timely response may be necessary under the instructions and deadline in the notice.
Claimants should verify that a message corresponds to their filed claim and use the official administrator process. OCA cannot cure a deficiency, upload records, or extend an administrator response deadline.
No. The extended claim deadline was April 17, 2025. Current work concerns timely submissions and does not reopen the claim portal. A consumer who learns about the litigation after final approval cannot join through OCA.
A timely claimant should keep the confirmation, unique identifiers, supporting documents, and any deficiency response. Avoid sharing prescription histories, insurance data, or tax information with an unofficial service.
This settlement focuses on prescription pricing and the Walgreens Prescription Savings Club’s relationship to usual and customary price reporting. It is not a general refund for every Walgreens purchase and does not cover unrelated employment, data breach, or retail-pricing disputes.
Eligibility requires the use of prescription insurance benefits during the defined period. Cash-only prescription purchases are not automatically covered by this settlement.
The next meaningful public update would be confirmation that finality and claims processing are complete, followed by payment authorization or a distribution date. Until the official site posts that information, a precise payout date would be speculation.
Claimants should monitor official correspondence and the settlement website. OCA will frame any future update around the actual procedural stage rather than assuming that approval and payment happen at the same time.
Review the latest information on the official Walgreens Savings Club settlement website.
Case
Russo et al. v. Walgreen Co.
Case Number
1:17-cv-02246
Court
U.S. District Court, Northern District of Illinois
Class Period
January 1, 2007–November 18, 2024
Settlement Fund
$100,000,000
Claim Deadline
April 17, 2025
Final Approval
March 31, 2026
Payment Stage
Claims processing; no public distribution date
For more class actions, recalls, and refunds, keep scrolling below.